NVCR News and Press, NovoCure Limited From 01/04/24

Novocure (NASDAQ: NVCR) today announced the appointment of Nicolas Leupin, M.D., Ph.D., MBA to the role of Chief Medical Officer. Dr. Leupin brings a proven track record of leadership and accomplishment in the biotechnology and pharmaceutical industries, as well as extensive experience as a medic...

2023-12-27 14:59:02 ET More on NovoCure NovoCure: Significant Upside Even Without A Breakthrough NovoCure Limited 2023 Q3 - Results - Earnings Call Presentation NovoCure Limited (NVCR) Q3 2023 Earnings Call Transcript Novocure to eliminate 13% of workforce in...

Novocure (NASDAQ: NVCR) announced today that management will participate in the 42 nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at 7:30 a.m. PST o...

2023-12-20 11:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-28 11:35:05 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rivian (NASDAQ: RIVN ) stock is a hot topic on Tuesday after Evercore ISI weighed in on the electric vehicle (EV) company’s shares. The big news here is Evercore ISI ...

2023-11-28 11:15:52 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips FuelCell Energy (NASDAQ: FCEL ) stock is rising higher on Tuesday after the fuel cell energy company announced a collaboration with IBM (NYSE: IBM ). This agreem...

2023-11-28 10:51:43 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Novocure (NASDAQ: NVCR ) layoffs are in the news after the company announced that it will be cutting 13% of its workers in a restructuring effort. Those layoffs will see the...

2023-11-28 07:51:52 ET Novocure ( NASDAQ: NVCR ) announced on Tuesday plans to lay off 13% of its current workforce as part of a strategic restructuring to cut down on expenses. The Root, Switzerland-based oncology company outlined a series of actions to strengthen and optim...

Prioritizing metastatic non-small cell lung cancer launch and focusing research and development activities in areas of greatest anticipated value creation Expected reduction in residual operating expenses of approximately $60 million, including a reduction in headcount of approximately 20...

2023-11-25 16:32:53 ET More on BioCryst Pharmaceuticals, Crinetics Pharmaceuticals, etc. Mirum Pharmaceuticals, Inc. (MIRM) Q3 2023 Earnings Call Transcript BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2023 Earnings Call Transcript Immunocore: First Half Of 2024 IMC-F106...